Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon

A new research has found that Pycnogenol? is more effective than Daflo...According to the journal of Clinical and Applied Thrombosis/Hemato...About 500000 people in the United States develop leg ulcers due t... Chronic venous insufficiency is caused when leg veins cannot pump...Researchers at L'Aquila University in Italy conducted a comparativ...

A new research has found that Pycnogenol? is more effective than Daflon?, a combined form of diosmin and hesperidin commonly used to treat chronic venous insufficiency// (CVI).

According to the journal of Clinical and Applied Thrombosis/Hematosis, the supplementation of Pycnogenol? shows increased symptom reduction in the patients suffering from Chronic venous insufficiency. It is an antioxidant extracted from the bark of French maritime pine tree. The study led for 35 years shows its ability to improve blood flow and increase the strength of venous walls. Research shows Pycnogenol? more effective than Daflon?, a combined form of diosmin and hesperidin commonly used to treat CVI. The former drug is found to be more effective in treating the symptoms of CVI mainly edema, tight calves, skin alterations, pain during walking, and swelling limbs.

About 500,000 people in the United States develop leg ulcers due to CVI. If left untreated, leg and ankle swelling can lead to dangerous conditions such as deep vein thrombosis (DVT). Previous studies have shown Pycnogenol? to be effective in encouraging improved circulation and helping to prevent travel-related DVT. Like varicose veins, spider veins also develop if edema is left untreated.

"Chronic venous insufficiency is caused when leg veins cannot pump enough blood back into the heart. When people are not active, blood pools in their leg veins, legs and ankles can become swollen," said Peter Rohdewald, Ph.D. and researcher of the study. "Eventually, some of the valves cannot hold the weight of excessive blood, which then adds more pressure onto the next valve further downwards. Ultimately, the inability to prevent the liquid in the blood from seeping into the tissue is what causes edema, a common condition of CVI."

Researchers at L'Aquila University in Italy conducted a comparative analysis by supplementing 86 patients with severe CVI with Pycnogenol? and Daflon?. Each grou
p supplemented daily for eight weeks. Patients who supplemented with Pycnogenol? received either 150 mg or 300 mg, while Daflon? patients supplemented with 1000 mg.

Ankle swelling was measured before 10 a.m. to avoid the swelling effect of standing and again after 30 minutes of resting with feet elevated. Measurements were taken at the beginning of the study and after four and eight weeks of treatment. A composite, analogue score based on signs and symptoms (edema, pain, restless limbs, subjective swelling, and skin alterations/redness) was recorded by patients. A second evaluation of edema was made by another physician.

After eight weeks of treatment, patients who supplemented with Pycnogenol? experienced decreased ankle swellings by 35 percent, while Daflon treatment decreased ankle swelling by 19 percent. A composite score for edema including pain, restless legs, feeling of heavy swollen legs, and skin alterations was found to be decreased with Pycnogenol? by 64%, whereas Daflon? was only half as effective, lowering the composite edema score by 32%.

The transdermal oxygen and carbon dioxide concentration in the lower legs was estimated with small sensors attached to the skin. Pycnogenol? treatment was found to significantly increase tissue oxygen and lower CO2, suggesting a considerable improvement in blood circulation to the legs. Daflon?, in contrast, did not yield any significant effect on the tissue oxygenation and apparently does not improve blood circulation to the legs.

"Interestingly, this study demonstrated that supplementation with a very high dosage of 300 mg Pycnogenol? a day did not yield significantly better effects than treatment with 150 mg Pycnogenol?, with the exception of the composite edema score, which improved better with the higher dosage," said Rohdewald.

Continuous stretching from CVI permanently enlarges veins. Past studies have shown that treating edema with Pycnogenol? prev
ents the development of spider veins. Pycnogenol? also helps prevent existing spider veins from getting larger and more prominent. When edema is successfully treated, the increased pressure on veins gets normalized, preventing the veins from further increasing in size.

"Pycnogenol? has demonstrated its efficacy and safety in several clinical trials and symptoms of CVI have been reduced significantly by Pycnogenol? in controlled studies. We were pleased to see that not only did Pycnogenol? decrease CVI symptoms, but the results were significantly more successful then the prescription drug used for treating CVI," said Rohdewald.

(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...

(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...

(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...

(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...

(Date:12/8/2016)... Pa. , Dec. 8, 2016 Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...